2:35 PM
 | 
Apr 06, 2018
 |  BioCentury  |  Finance

China’s exchange options

Comparing fast track pilot for mainland China listings to revamped HKEX

A new fast track to listing on China’s stock exchanges could provide emerging biotechs with an avenue to public funding on the mainland, but it’s not yet clear whether it will be enough to court companies away from the Hong Kong exchange, which is implementing rules allowing pre-revenue biotechs to list on its main board.

On March 30, China’s State Council approved a pilot program by the China Securities Regulatory Commission to prioritize share issuances for high market cap companies in several tech fields, including biomedicine.

“The Hong Kong market or another alternative market might be a better opportunity.”

Read the full 472 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD